Humanised monoclonal antibody therapy for rheumatoid arthritis.
Monoclonal antibodies that target T cells have shown some benefit in rheumatoid arthritis although responses have not been long lasting. This is partly due to insufficient therapy consequent upon antibody immunogenicity. Use of humanised antibodies, which are expected to be less foreign to man than...
主要な著者: | Isaacs, J, Watts, R, Hazleman, B, Hale, G, Keogan, M, Cobbold, S, Waldmann, H |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
1992
|
類似資料
-
HUMANIZED MONOCLONAL-ANTIBODY THERAPY IN RHEUMATOID-ARTHRITIS
著者:: Isaacs, J, 等
出版事項: (1992) -
Survival of patients after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
著者:: Isaacs, J, 等
出版事項: (2004) -
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
著者:: Isaacs, J, 等
出版事項: (2005) -
Long-term survival after lymphocytotoxic monoclonal antibody therapy for rheumatoid arthritis
著者:: Isaacs, J, 等
出版事項: (2005) -
Humanized monoclonal antibody treatment in rheumatoid arthritis.
著者:: Kyle, V, 等
出版事項: (1991)